Ingénierie de charpentes protéiques comme alternative aux anticorps - De la recherche au développement clinique

Thierry Wurch; Peter Lowe; Alain Beck; Nathalie Corvaia

doi:10.1051/medsci/200925121169

Accueil

Tous les numéros

Volume 25 / Numéro 12 (Décembre 2009)

Med Sci (Paris), 25 12 (2009) 1169-1172

Références

Accès gratuit

Numéro		Med Sci (Paris) Volume 25, Numéro 12, Décembre 2009 Anticorps monoclonaux en thérapeutique


Page(s)		1169 - 1172
Section		III - Un futur en développement
DOI		https://doi.org/10.1051/medsci/200925121169
Publié en ligne		15 décembre 2009

Wurch T, Lowe P, Caussanel V, et al. Development of novel protein scaffolds as alternatives to whole antibodies for imaging and therapy: status on discovery research and clinical validation. Curr Pharm Biotechnol 2008; 9 : 502–9. [Google Scholar]
Koide A, Bailey CW, Huang X, et al. The fibronectin type III domain as a scaffold for novel binding proteins. J Mol Biol 1998; 284 : 1141–51. [Google Scholar]
Koide A, Abbatiello S, Rothgery L, et al. Probing protein conformational changes in living cells by using designer binding proteins: application to the estrogen receptor. Proc Natl Acad Sci USA 2002; 99 : 1253–8. [Google Scholar]
Parker MH, Chen Y, Danehy F, et al. Antibody mimics based on human fibronectin type three domain engineered for thermostability and high-affinity binding to vascular endothelial growth factor receptor two. Protein Eng Des Sel 2005; 18 : 435–44. [Google Scholar]
Mamluk R, Carvajal IM, Bates JM, et al. Preclinical development of a potent VEGFR-2 antagonist based on a novel protein scaffold (AdNectin). Proc Amer Assoc Cancer Res 2005; 46 : Abstract nr 3037. [Google Scholar]
Carvajal IM, Bates JM, Sort S, et al. A Novel inhibitor for VEGFR-2 ; emerging advantages of blocking the VEGFR-2 receptor in the VEGF pathway. Proc Am Assoc Cancer Res 2006; 47 : 972 (abstract). [Google Scholar]
Sweeney CJ, Chriorean EG, Mita MM, et al. Phase I study of CT-322, first Adnectin protein therapeutic and potent inhibitor of VEGFR-2, in patients (pts) with advanced solid tumors (ST). J Clin Oncol 2008; 26 : 3523 (abstract). [Google Scholar]
Nilsson FY, Tolmachev V. Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy. Curr Opin Drug Discov Dev 2007; 10 : 167–75. [Google Scholar]
Orlova A, Magnusson M, Eriksson TL, et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res 2006; 66 : 4339–48. [Google Scholar]
Silverman J, Liu Q, Bakker A, et al. Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains. Nat Biotechnol 2005; 23 : 1556–61. [Google Scholar]
Markland W, Ley AC, Ladner RC. Iterative optimization of high-affinity protease inhibitors using phage display. 2. Plasma kallikrein and thrombin. Biochemistry 1996; 35 : 8058–67. [Google Scholar]
Williams A, Baird LG. DX-88 and HAE: a developmental perspective. Transfus Apher Sci 2003; 29 : 255–8. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.

[1] Wurch T, Lowe P, Caussanel V, et al. Development of novel protein scaffolds as alternatives to whole antibodies for imaging and therapy: status on discovery research and clinical validation. Curr Pharm Biotechnol 2008; 9 : 502–9. [Google Scholar]

[2] Koide A, Bailey CW, Huang X, et al. The fibronectin type III domain as a scaffold for novel binding proteins. J Mol Biol 1998; 284 : 1141–51. [Google Scholar]

[3] Koide A, Abbatiello S, Rothgery L, et al. Probing protein conformational changes in living cells by using designer binding proteins: application to the estrogen receptor. Proc Natl Acad Sci USA 2002; 99 : 1253–8. [Google Scholar]

[4] Parker MH, Chen Y, Danehy F, et al. Antibody mimics based on human fibronectin type three domain engineered for thermostability and high-affinity binding to vascular endothelial growth factor receptor two. Protein Eng Des Sel 2005; 18 : 435–44. [Google Scholar]

[5] Mamluk R, Carvajal IM, Bates JM, et al. Preclinical development of a potent VEGFR-2 antagonist based on a novel protein scaffold (AdNectin). Proc Amer Assoc Cancer Res 2005; 46 : Abstract nr 3037. [Google Scholar]

[6] Carvajal IM, Bates JM, Sort S, et al. A Novel inhibitor for VEGFR-2 ; emerging advantages of blocking the VEGFR-2 receptor in the VEGF pathway. Proc Am Assoc Cancer Res 2006; 47 : 972 (abstract). [Google Scholar]

[7] Sweeney CJ, Chriorean EG, Mita MM, et al. Phase I study of CT-322, first Adnectin protein therapeutic and potent inhibitor of VEGFR-2, in patients (pts) with advanced solid tumors (ST). J Clin Oncol 2008; 26 : 3523 (abstract). [Google Scholar]

[8] Nilsson FY, Tolmachev V. Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy. Curr Opin Drug Discov Dev 2007; 10 : 167–75. [Google Scholar]

[9] Orlova A, Magnusson M, Eriksson TL, et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res 2006; 66 : 4339–48. [Google Scholar]

[10] Silverman J, Liu Q, Bakker A, et al. Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains. Nat Biotechnol 2005; 23 : 1556–61. [Google Scholar]

[11] Markland W, Ley AC, Ladner RC. Iterative optimization of high-affinity protease inhibitors using phage display. 2. Plasma kallikrein and thrombin. Biochemistry 1996; 35 : 8058–67. [Google Scholar]

[12] Williams A, Baird LG. DX-88 and HAE: a developmental perspective. Transfus Apher Sci 2003; 29 : 255–8. [Google Scholar]